Literature DB >> 33050859

Progress on the Mechanism for Aspirin's Anti-tumor Effects.

Lin Zheng1, Weibiao Lv1, Yuanqing Zhou1, Xu Lin2, Jie Yao1.   

Abstract

Since its discovery more than 100 years ago, aspirin has been widely used for its antipyretic, analgesic, anti-inflammatory, and anti-rheumatic activities. In addition to these applications, it is increasingly becoming clear that the drug also has great potential in the field of cancer. Here, we briefly review the current insights on aspirin's anti-tumor effects. These are multiple and vary from inhibiting the major cellular mTOR pathways, acting as a calorie-restricted mimetic by inhibition of energy production, suppressing platelet aggregation and granule release, inhibiting the immune escape of tumor cells, to decreasing inflammatory responses. We consider these five mechanisms of action the most significant for aspirin's anti-tumor effects, whereby the anti-tumor effect may ultimately stem from its inhibition of energy metabolism, platelet function, and inflammatory response. As such, aspirin can play an important role to reduce the occurrence, proliferation, and metastasis of various types of tumors. However, most of the collected data are still based on epidemiological investigations. More direct and effective evidence is needed, and the side effects of aspirin intake need to be solved before this drug can be widely applied in cancer treatment. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Aspirin; acetyl salicylic acid; anti-tumor activity; cancer; cellular mTOR pathways; inflammatory

Year:  2021        PMID: 33050859     DOI: 10.2174/1389450121999201013152931

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  2 in total

Review 1.  Metformin: A promising drug for human cancers.

Authors:  Hongnian Wu; Dan Huang; Hong Zhou; Xueqin Sima; Zhe Wu; Yanling Sun; Long Wang; Ying Ruan; Qian Wu; Feng Wu; Tonghui She; Ying Chu; Qizhi Huang; Zhifeng Ning; Hao Zhang
Journal:  Oncol Lett       Date:  2022-05-12       Impact factor: 3.111

2.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.